MAP2K7 and glioblastoma: In sum, these data suggest distinct mechanisms mediate selumetinib response across different glioblastoma cellular states, with MES-like cells maintaining dependence on Ras/RAF/MEK/ERK signaling while non-MES cells are associated with altered glial differentiation to persist following selumetinib treatment.